Effect of a single 5 mg infusion of zoledronic acid on bone turnover markars vs. oral risedronate (5 mg/day) over 1 year in patients with glucocorticoid-induced osteoporosis
Philip N. Sambrook, J.-P. Devogelaer, Jean‐Yves Reginster, Kenneth G. Saag, C. Roux, Chak Sing Lau, P. Papanastasiou, Oliver Schönborn‐Kellenberger, K. Maylandt, T. Fashola, Peter G Mesenbrink, David M. Reid
Abstract